Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry
Background Real-world data on the use of interleukin-17 (IL-17) inhibitors for the treatment of psoriasis are limited. Objective To evaluate and compare the efficacy, safety, and drug survival of IL-17 inhibitors. Methods This retrospective study analyzed the BIOREP registry data of patients treated...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-08-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2022.2082354 |
| _version_ | 1797683475058262016 |
|---|---|
| author | Martina Kojanova Jan Hugo Barbora Velackova Petra Cetkovska Jorga Fialova Tomas Dolezal Martin Tichy Spyridon Gkalpakiotis |
| author_facet | Martina Kojanova Jan Hugo Barbora Velackova Petra Cetkovska Jorga Fialova Tomas Dolezal Martin Tichy Spyridon Gkalpakiotis |
| author_sort | Martina Kojanova |
| collection | DOAJ |
| description | Background Real-world data on the use of interleukin-17 (IL-17) inhibitors for the treatment of psoriasis are limited. Objective To evaluate and compare the efficacy, safety, and drug survival of IL-17 inhibitors. Methods This retrospective study analyzed the BIOREP registry data of patients treated with at least one IL-17 inhibitor (secukinumab, ixekizumab, and brodalumab). Results In total, 949 patients were included. The improvement in PASI score was significant for all drugs, and the proportion of patients achieving PASI 75, 90, and 100 after both 3 and 24 months of therapy was highest for brodalumab, followed by ixekizumab and secukinumab. The Dermatology Life Quality Index score decreased to ˂3 after 3 months and to ˂2 after 24 months of therapy for all inhibitors. Loss of effectiveness was the major reason for discontinuation in 17.2% of patients, followed by adverse events in 3.2% of patients. The drug survival probability was the highest for brodalumab, followed by ixekizumab and secukinumab. Negative predictors for treatment discontinuation were obesity and the number of treatment lines, whereas a positive predictor was the presence of concomitant psoriatic arthritis; sex had no influence. Conclusion This real-life study demonstrated the effectiveness and good safety profile of all currently available IL-17 inhibitors. |
| first_indexed | 2024-03-12T00:14:57Z |
| format | Article |
| id | doaj.art-728b6710d1704284938f5de505be44cf |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:14:57Z |
| publishDate | 2022-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-728b6710d1704284938f5de505be44cf2023-09-15T14:28:52ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-08-013362827283710.1080/09546634.2022.20823542082354Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registryMartina Kojanova0Jan Hugo1Barbora Velackova2Petra Cetkovska3Jorga Fialova4Tomas Dolezal5Martin Tichy6Spyridon Gkalpakiotis7Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles UniversityDepartment of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University HospitalValue OutcomesDepartment of Dermatovenereology, Faculty of Medicine in Pilsen, Charles UniversityDepartment of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles UniversityValue OutcomesDepartment of Dermatology and Venereology, Faculty of Medicine and Dentistry, University Hospital OlomoucDepartment of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University HospitalBackground Real-world data on the use of interleukin-17 (IL-17) inhibitors for the treatment of psoriasis are limited. Objective To evaluate and compare the efficacy, safety, and drug survival of IL-17 inhibitors. Methods This retrospective study analyzed the BIOREP registry data of patients treated with at least one IL-17 inhibitor (secukinumab, ixekizumab, and brodalumab). Results In total, 949 patients were included. The improvement in PASI score was significant for all drugs, and the proportion of patients achieving PASI 75, 90, and 100 after both 3 and 24 months of therapy was highest for brodalumab, followed by ixekizumab and secukinumab. The Dermatology Life Quality Index score decreased to ˂3 after 3 months and to ˂2 after 24 months of therapy for all inhibitors. Loss of effectiveness was the major reason for discontinuation in 17.2% of patients, followed by adverse events in 3.2% of patients. The drug survival probability was the highest for brodalumab, followed by ixekizumab and secukinumab. Negative predictors for treatment discontinuation were obesity and the number of treatment lines, whereas a positive predictor was the presence of concomitant psoriatic arthritis; sex had no influence. Conclusion This real-life study demonstrated the effectiveness and good safety profile of all currently available IL-17 inhibitors.http://dx.doi.org/10.1080/09546634.2022.2082354psoriasisil-17 inhibitorsbrodalumabixekizumabsecukinumabreal-worldbiological therapyregistriesbiorep |
| spellingShingle | Martina Kojanova Jan Hugo Barbora Velackova Petra Cetkovska Jorga Fialova Tomas Dolezal Martin Tichy Spyridon Gkalpakiotis Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry Journal of Dermatological Treatment psoriasis il-17 inhibitors brodalumab ixekizumab secukinumab real-world biological therapy registries biorep |
| title | Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry |
| title_full | Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry |
| title_fullStr | Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry |
| title_full_unstemmed | Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry |
| title_short | Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry |
| title_sort | efficacy safety and drug survival of patients with psoriasis treated with il 17 inhibitors brodalumab ixekizumab and secukinumab real world data from the czech republic biorep registry |
| topic | psoriasis il-17 inhibitors brodalumab ixekizumab secukinumab real-world biological therapy registries biorep |
| url | http://dx.doi.org/10.1080/09546634.2022.2082354 |
| work_keys_str_mv | AT martinakojanova efficacysafetyanddrugsurvivalofpatientswithpsoriasistreatedwithil17inhibitorsbrodalumabixekizumabandsecukinumabrealworlddatafromtheczechrepublicbiorepregistry AT janhugo efficacysafetyanddrugsurvivalofpatientswithpsoriasistreatedwithil17inhibitorsbrodalumabixekizumabandsecukinumabrealworlddatafromtheczechrepublicbiorepregistry AT barboravelackova efficacysafetyanddrugsurvivalofpatientswithpsoriasistreatedwithil17inhibitorsbrodalumabixekizumabandsecukinumabrealworlddatafromtheczechrepublicbiorepregistry AT petracetkovska efficacysafetyanddrugsurvivalofpatientswithpsoriasistreatedwithil17inhibitorsbrodalumabixekizumabandsecukinumabrealworlddatafromtheczechrepublicbiorepregistry AT jorgafialova efficacysafetyanddrugsurvivalofpatientswithpsoriasistreatedwithil17inhibitorsbrodalumabixekizumabandsecukinumabrealworlddatafromtheczechrepublicbiorepregistry AT tomasdolezal efficacysafetyanddrugsurvivalofpatientswithpsoriasistreatedwithil17inhibitorsbrodalumabixekizumabandsecukinumabrealworlddatafromtheczechrepublicbiorepregistry AT martintichy efficacysafetyanddrugsurvivalofpatientswithpsoriasistreatedwithil17inhibitorsbrodalumabixekizumabandsecukinumabrealworlddatafromtheczechrepublicbiorepregistry AT spyridongkalpakiotis efficacysafetyanddrugsurvivalofpatientswithpsoriasistreatedwithil17inhibitorsbrodalumabixekizumabandsecukinumabrealworlddatafromtheczechrepublicbiorepregistry |